BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
11/15/2023 1:46:53 PM | Browse: 264 | Download: 792
 |
Received |
|
2023-05-23 09:54 |
|
Peer-Review Started |
|
2023-05-23 09:56 |
|
First Decision by Editorial Office Director |
|
2023-07-31 17:22 |
|
Return for Revision |
|
2023-07-31 17:22 |
|
Revised |
|
2023-08-31 22:23 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2023-10-11 01:11 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2023-10-11 06:05 |
|
Articles in Press |
|
2023-10-11 06:05 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2023-11-06 09:55 |
|
Publish the Manuscript Online |
|
2023-11-15 13:46 |
| ISSN |
1948-5204 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Retrospective Study |
| Article Title |
Mitomycin C and capecitabine: An additional option as an advanced line therapy in patients with metastatic colorectal cancer
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Gil Mullin, Michal Sternschuss, Yosef Landman, Aaron Sulkes and Baruch Brenner |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Baruch Brenner, MD, Professor, Department of Oncology, Davidoff Cancer Center, Beilinson Campus, 39 Jabotinski Street, Petah-Tikva 4941492, Israel. brennerb@clalit.org.il |
| Key Words |
Colorectal cancer; Metastatic cancer; Chemotherapy; Mitomycin C; Capecitabine; Advanced line treatment |
| Core Tip |
Survival with metastatic colorectal cancer has improved significantly. However, when the disease becomes refractory, patients are left with limited options. Mitomycin C (MMC) and capecitabine combination is a potential treatment option for mCRC patients beyond standard lines of treatment. Only a few small studies have tested it in the advanced-line setting, with contradictory results. We present our experience using the MMC/capecitabine combination. Our findings suggest that MMC/capecitabine is a safe, well-tolerated regimen. Ours is the largest series on the use of MMC/capecitabine in refractory mCRC. We were able to identify well-defined subgroups which derived clinical benefit from this combination. |
| Publish Date |
2023-11-15 13:46 |
| Citation |
Mullin G, Sternschuss M, Landman Y, Sulkes A, Brenner B. Mitomycin C and capecitabine: An additional option as an advanced line therapy in patients with metastatic colorectal cancer. World J Gastrointest Oncol 2023; 15(11): 1913-1924 |
| URL |
https://www.wjgnet.com/1948-5204/full/v15/i11/1913.htm |
| DOI |
https://dx.doi.org/10.4251/wjgo.v15.i11.1913 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
